Allen S. Melemed

1.9k total citations
43 papers, 1.4k citations indexed

About

Allen S. Melemed is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Allen S. Melemed has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Allen S. Melemed's work include Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Allen S. Melemed is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Allen S. Melemed collaborates with scholars based in United States, Spain and Germany. Allen S. Melemed's co-authors include Kathy S. Albain, Antonio Llombart‐Cussac, A Płużańska, G. Calderillo-Ruiz, Lorinda Simms, Joyce O’Shaughnessy, Shona Nag, Jagdev Singh Sekhon, Janusz Rolski and John Ryder and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Allen S. Melemed

42 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allen S. Melemed United States 20 844 396 352 237 200 43 1.4k
Daniel Vorobiof South Africa 18 938 1.1× 300 0.8× 390 1.1× 153 0.6× 125 0.6× 61 1.6k
Cynthia Osborne United States 9 1.0k 1.2× 432 1.1× 282 0.8× 441 1.9× 233 1.2× 12 1.5k
Diana Lake United States 22 1.2k 1.4× 465 1.2× 452 1.3× 337 1.4× 109 0.5× 70 1.7k
Jacobus J. M. van der Hoeven Netherlands 26 929 1.1× 526 1.3× 338 1.0× 435 1.8× 99 0.5× 60 2.0k
Ted Vandenberg Canada 19 1.4k 1.7× 761 1.9× 585 1.7× 381 1.6× 279 1.4× 39 2.0k
Mohammad Jahanzeb United States 17 960 1.1× 390 1.0× 547 1.6× 356 1.5× 138 0.7× 32 1.5k
Aafke H. Honkoop Netherlands 17 1.1k 1.3× 495 1.3× 364 1.0× 189 0.8× 60 0.3× 33 1.5k
Isabel Chirivella Spain 16 1.1k 1.3× 254 0.6× 453 1.3× 246 1.0× 200 1.0× 53 1.5k
Roberta Maltoni Italy 21 722 0.9× 376 0.9× 299 0.8× 338 1.4× 129 0.6× 84 1.2k
Filipa Lynce United States 21 1.3k 1.5× 474 1.2× 456 1.3× 571 2.4× 323 1.6× 110 1.9k

Countries citing papers authored by Allen S. Melemed

Since Specialization
Citations

This map shows the geographic impact of Allen S. Melemed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allen S. Melemed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allen S. Melemed more than expected).

Fields of papers citing papers by Allen S. Melemed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allen S. Melemed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allen S. Melemed. The network helps show where Allen S. Melemed may publish in the future.

Co-authorship network of co-authors of Allen S. Melemed

This figure shows the co-authorship network connecting the top 25 collaborators of Allen S. Melemed. A scholar is included among the top collaborators of Allen S. Melemed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allen S. Melemed. Allen S. Melemed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arrillaga‐Romany, Isabel, Andrew B. Lassman, Susan L. McGovern, et al.. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology. 26(Supplement_2). S173–S181. 25 indexed citations
2.
Arrillaga‐Romany, Isabel, Andrew B. Lassman, Susan L. McGovern, et al.. (2023). P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA. Neuro-Oncology. 25(Supplement_2). ii84–ii84.
3.
Magnuson, Allison, Suanna S. Bruinooge, Harpreet Singh, et al.. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research. 27(9). 2424–2429. 44 indexed citations
4.
Forde, Patrick M., P. Bonomi, Alice T. Shaw, et al.. (2020). Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clinical Lung Cancer. 21(4). 295–307. 10 indexed citations
5.
Bonomi, Philip, Gideon M. Blumenthal, Andrea Stern Ferris, et al.. (2018). Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology. 13(6). 748–751. 10 indexed citations
6.
7.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2017). Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 16(10). 2215–2222. 34 indexed citations
8.
Smyth, Emily Nash, Wei Shen, Lee Bowman, et al.. (2016). Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health and Quality of Life Outcomes. 14(1). 52–52. 29 indexed citations
9.
10.
Fu, Haoda, Yanping Wang, Jingyi Liu, Pandurang M. Kulkarni, & Allen S. Melemed. (2012). Joint modeling of progression‐free survival and overall survival by a Bayesian normal induced copula estimation model. Statistics in Medicine. 32(2). 240–254. 21 indexed citations
11.
12.
Paridaens, Robert, Luc Dirix, Herlinde Dumez, et al.. (2007). Phase I/II Pharmacokinetic Study of Pemetrexed and Epirubicin in Patients with Locally Advanced or Metastatic Breast Cancer. Clinical Breast Cancer. 7(11). 861–866. 5 indexed citations
13.
Melemed, Allen S., et al.. (2007). Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 25(31). 4967–4973. 57 indexed citations
14.
Melemed, Allen S., T. A. Larson, Arkadiusz Z. Dudek, et al.. (2005). Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response. Journal of Clinical Oncology. 23(16_suppl). 7257–7257. 6 indexed citations
15.
O’Shaughnessy, Joyce, Joanne L. Blum, Robert Mennel, et al.. (2005). Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast Cancer. Clinical Breast Cancer. 6(2). 143–149. 44 indexed citations
16.
Köse, Mehmet Faruk, Jozef Šufliarský, S. Beslija, et al.. (2004). A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecologic Oncology. 96(2). 374–380. 25 indexed citations
17.
18.
McMeekin, D. Scott, Alan N. Gordon, Jeffrey M. Fowler, et al.. (2003). A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecologic Oncology. 90(1). 64–69. 55 indexed citations
19.
Cotton, Jenny, et al.. (1996). Extranodal spread of anaplastic large cell (CD30+) lymphoma presenting as a cutaneous perivascular infiltrate. Journal of Cutaneous Pathology. 23(4). 323–327. 2 indexed citations
20.
Tolins, J P, et al.. (1991). Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids. 26(12Part2). 1218–1222. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Vorobiof Breakdown of academic impact, for papers by Cynthia Osborne Breakdown of academic impact, for papers by Diana Lake Breakdown of academic impact, for papers by Jacobus J. M. van der Hoeven Breakdown of academic impact, for papers by Ted Vandenberg Breakdown of academic impact, for papers by Mohammad Jahanzeb Breakdown of academic impact, for papers by Aafke H. Honkoop Breakdown of academic impact, for papers by Isabel Chirivella Breakdown of academic impact, for papers by Roberta Maltoni Breakdown of academic impact, for papers by Filipa Lynce
Rankless by CCL
2026